ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -1,451.5% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 332.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -1,862.6% |
| EPS Diluted | -0.007 | -2.27 | -3.99 | -3.49 |
| % Growth | 99.7% | 43.1% | -14.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |